• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

INFLIXIMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • INFLIXIMAB chembl:CHEMBL1201581 ApprovedImmunotherapy

    Alternate Names:

    INFLIXIMAB
    ABP 710
    BOW015
    REMICADE
    REMSIMA
    NI-071
    INFLECTRA
    TA-650
    CA2
    CA2 ????
    IG GAMMA-1 CHAIN C REGION
    rxcui:191831
    drugbank:00065
    chemidplus:170277-31-3
    chembl:CHEMBL1201581

    Drug Info:

    FDA Approval approved
    Drug Class monoclonal antibody
    Drug Indications antiinflammatory agent,DMARD
    Drug Class immunosuppressive agents
    Year of Approval 1998
    (3 More Sources)

    Publications:

    Duftner et al., 2006, Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis., Ann. Rheum. Dis.
    Mimura, 2007, [Selection of one of the TNF blockers; infliximab and etanercept]., Nippon Rinsho
    Magro et al., 2005, Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis?, Inflamm. Bowel Dis.
    Sapienza et al., 2004, Treatment of pyoderma gangrenosum with infliximab in Crohn's disease., Dig. Dis. Sci.
    Shen et al., 2005, Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept., Aliment. Pharmacol. Ther.
    Braun et al., 2005, Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept., Arthritis Rheum.
    Mori et al., 2006, Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody., Mod Rheumatol
    Maini et al., 2002, How does infliximab work in rheumatoid arthritis?, Arthritis Res.
    Popa et al., 2005, Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy., Cytokine
    Tobin et al., 2005, TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis., BioDrugs
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Danese et al., 2006, TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease., J. Immunol.
    Song GG et al., 2015, Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis., Pharmacogenomics
    Swierkot J et al., 2015, Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis., Joint Bone Spine
    Tong Q et al., 2013, Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis., Pharmacogenomics
    Tong Q et al., 2012, TNF-α -857 and -1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis., Pharmacogenomics
    Lacruz-Guzmán D et al., 2013, Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis., Eur J Clin Pharmacol
    Zeng Z et al., 2013, Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis., Mod Rheumatol
    Daïen CI et al., 2012, TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis., Joint Bone Spine
    O'Rielly DD et al., 2009, TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis., Pharmacogenomics J
    Maxwell JR et al., 2008, Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis., Hum Mol Genet
    Marotte H et al., 2008, Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor., Arthritis Rheum
    Guis S et al., 2007, Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis., Arthritis Rheum
    Miceli-Richard C et al., 2008, A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis., Ann Rheum Dis
    Cuchacovich M et al., 2006, Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis., Scand J Rheumatol
    Lee YH et al., 2006, Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis., Rheumatol Int
    Seitz M et al., 2007, The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients., Rheumatology (Oxford)
    Kang et al., 2005, The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis., Rheumatology (Oxford)
    Mugnier B et al., 2003, Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis., Arthritis Rheum
    Louis E et al., 2002, A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism., Scand J Gastroenterol
    Mendrinou E et al., 2017, FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors., Pharmacogenomics J
    Dávila-Fajardo CL et al., 2015, FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis., Pharmacogenomics
    Montes A et al., 2014, Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis., Pharmacogenet Genomics
    Julià M et al., 2013, The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study., JAMA Dermatol
    Morales-Lara MJ et al., 2012, Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis., Joint Bone Spine
    Netea et al., 2003, Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression., Arthritis Rheum.
    Ovejero-Benito MC et al., 2018, Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis., Pharmacogenomics
    Canet LM et al., 2015, Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study., Pharmacogenet Genomics
    González-Lara L et al., 2015, The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients., Arch Dermatol Res
    Rooryck C et al., 2008, Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy., Clin Exp Rheumatol
    Julià A et al., 2014, PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis., Pharmacogenomics
    Julià A et al., 2015, Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis., Pharmacogenomics J
    Acosta-Colman I et al., 2013, GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis., Pharmacogenomics
    Pappas DA et al., 2013, Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis., Inflammation
    Miheller et al., 2005, [Improvement of bone metabolism after infliximab therapy in Crohn's disease]., Orv Hetil
    Montes A et al., 2015, FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors., Pharmacogenomics
    Tsukahara S et al., 2008, A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis., Ann Rheum Dis
    Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine
    Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol
    Dávila-Fajardo CL et al., 2014, Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome., Pharmacogenet Genomics
    Cui J et al., 2010, Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy., Arthritis Rheum
  • INFLIXIMAB   SLCO1C1

    Interaction Score: 6.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25493569 25403996 23651021


    Sources:
    PharmGKB

  • INFLIXIMAB   IVL

    Interaction Score: 3.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29192552


    Sources:
    PharmGKB

  • INFLIXIMAB   CCL3

    Interaction Score: 3.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16219708


    Sources:
    NCI

  • INFLIXIMAB   TNFRSF1B

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25850964 25537528 22129793 18565259


    Sources:
    PharmGKB

  • INFLIXIMAB   FCGR2A

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27044681 25823785 24667440 24048425


    Sources:
    PharmGKB

  • INFLIXIMAB   TRAF1

    Interaction Score: 2.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23007924


    Sources:
    PharmGKB

  • INFLIXIMAB   ATP5F1E

    Interaction Score: 1.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26307125


    Sources:
    PharmGKB

  • INFLIXIMAB   KLRD1

    Interaction Score: 1.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26453102


    Sources:
    PharmGKB

  • INFLIXIMAB   TNFRSF1A

    Interaction Score: 1.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22480748


    Sources:
    PharmGKB

  • INFLIXIMAB   TNF

    Interaction Score: 1.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name infliximab ,Remicade
    Novel drug target Established target
    Direct Interaction yes

    PMIDs:
    17642244 15674127 15481318 15691299 16052578 16622728 12110154 15804598 15691217 11752352 16456024 26244882 25311255 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17673491 17343250 16909270 16720636 15695296 12847678 12190096


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • INFLIXIMAB   IL12B

    Interaction Score: 1.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29192552


    Sources:
    PharmGKB

  • INFLIXIMAB   PTPRC

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23007924 20309874


    Sources:
    PharmGKB

  • INFLIXIMAB   HLA-E

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • INFLIXIMAB   CCL17

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16219708


    Sources:
    NCI

  • INFLIXIMAB   FCGR3A

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27044681 25823782 24048425 19005160


    Sources:
    PharmGKB

  • INFLIXIMAB   TLR4

    Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12847679


    Sources:
    NCI

  • INFLIXIMAB   BGLAP

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16130441


    Sources:
    NCI

  • INFLIXIMAB   IL6

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24253594


    Sources:
    PharmGKB

  • INFLIXIMAB   IL1B

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22960943


    Sources:
    PharmGKB

  • INFLIXIMAB   HLA-DRB1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: INFLIXIMAB

    • Version: 01-August-2011

    Alternate Names:
    INFLIXIMAB Primary Drug Name

    Drug Info:
    Year of Approval 1998
    Drug Class immunosuppressive agents

    Publications:

  • TdgClinicalTrial: INFLIXIMAB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiinflammatory agent,DMARD
    Drug Class monoclonal antibody
    FDA Approval approved

    Publications:

  • NCI: INFLIXIMAB

    • Version: 14-September-2017

    Alternate Names:
    C1789 NCI drug code

    Drug Info:

    Publications:
    Duftner et al., 2006, Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis., Ann. Rheum. Dis.
    Miheller et al., 2005, [Improvement of bone metabolism after infliximab therapy in Crohn's disease]., Orv Hetil
    Netea et al., 2003, Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression., Arthritis Rheum.

  • PharmGKB: infliximab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Morales-Lara MJ et al., 2012, Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis., Joint Bone Spine
    Cui J et al., 2010, Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy., Arthritis Rheum
    Pappas DA et al., 2013, Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis., Inflammation

  • TTD: Infliximab

    • Version: 2020.06.01

    Alternate Names:
    D0PG5G TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201581

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201581

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21